The abstract is read at the publisher; the summary is JClub's.
Anti-CD19 CAR macrophages engraft and persist up to 12 weeks in EAG mice, driving near-complete depletion of CD19+ B cells and improving kidney injury.
- Why it matters: Autoantibody-producing B cells drive autoimmune kidney disease, and existing B cell–depleting antibodies incompletely suppress humoral immunity.
- What they did: Murine macrophages were lentivirally engineered with an anti-CD19 CAR using an extracellular single-chain variable fragment linked to FcγRI and CD3ζ signaling domains, then administered to EAG mice immunized with human α3(IV)-NC1.
- The result: CAR-M treatment improved kidney outcomes by attenuating glomerulosclerosis and tubular injury, reducing glomerular IgG deposition and circulating autoantibodies, and lowering kidney infiltration of T cells and macrophages.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.